Investigating how protein methylation affects cell division and glioblastoma
Role of Protein Methylation in Cell Mitosis and Glioblastoma
This study is looking at how a specific protein called PRMT6 affects the growth of glioblastoma, a type of brain cancer, and how it might help us find better treatments, especially when combined with radiation therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10757324 on NIH RePORTER |
What this research studies
This research explores the role of protein methylation, specifically focusing on protein arginine methyltransferase 6 (PRMT6), in the development and treatment responses of glioblastoma (GBM). By studying how PRMT6 influences cell mitosis and tumor behavior through the methylation of specific proteins, the project aims to uncover new therapeutic targets. The researchers will utilize both genetic and pharmacological approaches to inhibit PRMT6 and its associated pathways, assessing their impact on tumor growth and response to radiation therapy. This work is designed to enhance our understanding of GBM biology and improve treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking innovative treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in targeting protein methylation in cancer therapies, indicating potential for success in this approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Cheng, Shi-Yuan — Northwestern University at Chicago
- Study coordinator: Cheng, Shi-Yuan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.